Showing results (731-740 of 782) with videos related to
Sort By:
Pageof 79
Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.Blood|January 17, 2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPaul G Richardson, Wanling Xie, Sundar Jagannath, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.Blood|April 14, 2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G Richardson, Edie Weller, Sagar Lonial, et al.Cell Reports|April 6, 2017
The Mutational Landscape of Circulating Tumor Cells in Multiple MyelomaYuji Mishima, Bruno Paiva, Jiantao Shi, et al.American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.Blood|November 21, 2024
Serum free light chains in a racially diverse population including African Americans and populations from South AfricaLuca Bertamini, Jean-Baptiste Alberge, David J Lee, et al.Blood Cancer Discovery|January 4, 2021
Revealing the impact of structural variants in multiple myelomaEven H Rustad, Venkata D Yellapantula, Dominik Glodzik, et al.Pageof 79